The potential of the CMB305 vaccine regimen to target NY-ESO-1 and improve outcomes for synovial sarcoma and myxoid/round cell liposarcoma patients

類似資料

• NY-ESO-1 is a Ubiquitous Immunotherapeutic Target Antigen for Patients with Myxoid/ Round Cell Liposarcoma
  著者:: Pollack, Seth M., 等
  出版事項: (2012)
• Exomic Analysis of Myxoid Liposarcomas, Synovial Sarcomas, and Osteosarcomas
  著者:: Joseph, Christine G., 等
  出版事項: (2013)
• Clinical outcomes of patients with advanced synovial sarcoma or myxoid/round cell liposarcoma treated at major cancer centers in the United States
  著者:: Pollack, Seth M., 等
  出版事項: (2020)
• A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1
  著者:: Somaiah, Neeta, 等
  出版事項: (2020)
• First-in-Human Treatment With a Dendritic Cell-targeting Lentiviral Vector-expressing NY-ESO-1, LV305, Induces Deep, Durable Response in Refractory Metastatic Synovial Sarcoma Patient
  著者:: Pollack, Seth M., 等
  出版事項: (2017)